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Sniary The clinical features and response to therapy of 32 Chinese patients with localised plasmacytoma
are presented, and a companson between extramedullary plasmacytoma (EMP) and solitary plasmacytoma of
bone (SPB) is made. Twenty-two patients had SPB and ten had EMP, accounting for 9% of all of our plasma
cell neoplasms. Both groups had a male predominance with a median age of 54 years for SPB and 63 years for
EMP. The common sites of SPB included vertebral bodies (15) and the skull (4). Most EMPs occurred in the
oronasopharynx (6) and paranasal sinuses (2). An M-protein was detected in eight patients with SPB and in
six with EMP. Seventeen patients with SPB and seven with EMP received radiation therapy, and all achieved
initial local control. The pattern of failure in 22 patients with SPB manifested as local recurrence in two,
multiple bone metastases without bone marrow plasmacytosis in two, multiple EMP progression in two, and
development of multiple myeloma (MM) in one. There were two local recurrences, one further solitary bone
involvement and one MM conversion in the EMP group. Local recurrence or dissemination was associated
with the appearance of M-protein or an increase in the M-protein level in both groups. There was no
significant difference in M-protein status or incidence and patterns of failure between the two groups. Patients
with EMP had a more favourable overall survival than those with SPB (P = 0.03). The 5 year disease-free
survival rate was 79% for EMP and 58% for SPB (P = 0.53). Patients aged less than 60 years had a better
overall survival in the SPB group, but location of tumour, presence of M-protein, radiation dose and
chemotherapy did not influence prognosis in either group. Our results indicate that adequate local therapy can
result in long-term survival with a low frequency of MM progression for patients with localised plas-
macytomas, and both EMP and SPB appear to be similar in terms of frequency and patterns of failure.
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Localised plasmacytomas are rare tumours, and account for
5-10% of all plasma cell neoplasms in Western countries
(Corwin & Lindberg, 1979; Knowling et at., 1983; Mayr et
al., 1990; Dimopoulos et al., 1992). Solitary plasmacytoma of
bone (SPB) and extramedullary plasmacytoma (EMP) have
been reported in most series to be distinct entities. Con-
siderable debate exists regarding the relationship of SPB and
EMP to multiple myeloma (MM). Most authors agree that
EMP has a different natural history from both SPB and MM
and believe that SPB is simply an early presentation of MM
(Wiltshaw, 1976; Corwin & Lindberg, 1979; Knowling et al.,
1983; Chak et al., 1987; Holland et al., 1992), whereas others
consider that SPB is a clinical entity distinct from MM
(Bataille & Sany, 1981; Delauche-Cavallier et al., 1988). Lit-
tle information is available from other parts of the world
regarding the incidence, natural history and patterns of pro-
gression of localised plasmacytomas.
In this study, a retrospective review of the clinical features,
the response to therapy and the course of the disease in 32
patients with SPB and EMP treated in a single institute in
Taiwan was undertaken. A comparison between SPB and
EMP was made, and we also compared the features of the
two groups in the present series with those reported in
Western series to increase understanding of the natural
courses of both SPB and EMP. In addition, an attempt was
made to identify the factors influencing the prognosis of
localised plasmacytomas.
Patients and methods
Patient population
Between January 1978 and April 1993, 356 consecutive
Chinese patients with newly diagnosed plasma cell malignan-
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cies were evaluated at the division of Hematology-Oncology,
Chang Gung Memorial Hospital, Taiwan. Of these patients,
32 had solitary plasmacytomas which were defined as (1)
having a radiologically solitary lytic bone lesion or soft-tissue
mass which was histologically proven to be a plasmacytoma,
(2) less than 5% plasma cells in the bone marrow at diag-
nosis and (3) no anaemia, hypercalcaemia or impairment of
renal function. Patients with M-protein in the serum or urine
at presentation were not excluded from the study if they met
the above criteria.
Clinical investigation
The initial clinical assessment included history and physical
examinations; complete blood cell counts, blood urea nitro-
gen, creatinine and calcium levels; bone marrow aspiration
and trephine biopsy; serum and urine protein electrophoresis
and immunoelectrophoresis; quantitation of serum immuno-
globulins and measurement of the 24 h Bence Jones protein
excretion; and full radiological skeletal surveys. For patients
with SPB, computerised tomography of the involved spine
and/or myelography were performed in those who presented
with spinal cord compression; for patients with EMP, com-
puterised tomography of the head and neck was performed
in patients with sinonasal lesions.
Patients were followed regularly to assess the local control
and patterns of failure after initial investigation and treat-
ment. M-protein was measured serially during and following
therapy. Repeated skeletal survey and bone marrow examina-
tion or other radiological studies were performed as indi-
cated. Local control with complete response was defined as
resolution of symptoms with no evidence of further plasma
cell proliferation and complete regression of detectable M-
protein. Local control with apparent remission was defined
as that for complete response but with a low constant M-
protein level. Patterns of failure included local recurrence,
disease progression with appearance of new lesion or
development of MM.Locda.d plasMr_bma inTawan
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Statistical analysis
Overall survival time was calculated from the time of diag-
nosis to the last follow-up date or date of death. Disease-free
survival was measured from the date of local control with
complete response or apparent remission to the date of local
recurrence, disease progression, death or last follow-up.
Patients in whom local control was not achieved were con-
sidered as treatment failure at zero time for the analysis of
disease-free survival. Survival curves were plotted using the
method of Kaplan and Meier with differences compared by
the log-rank test. Various patient characteristics were
analysed for their impact on survival and subsequent failure.
Fisher's exact test was used to determine the significance of
differences in the frequencies of various parameters between
the two groups (all P-values were two-sided).
Results
Of the 32 Chinese patients with solitary plasmacytomas, 22
had SPB and ten had EMP.
Solitary plasmacytoma ofbone
The clinical characteristics and response to treatment of the
22 patients with SPB are listed in Table I. There were 17
male and five female patients with ages ranging from 21 to 71
years (median 54 years). The sites of bone tumours were the
spine in 15 patients, with thoracic vertebra being the most
common site, the skull in four and one each for the clavicle,
ilium and femur. Half of the patients presented initially with
pain at the site of the bone lesions. Ten patients had a neuro-
logical deficit caused by spinal cord or nerve root compres-
sion. All four patients with plasmacytoma of the skull pres-
ented with a palpable mass.
All patients underwent surgery for pathological diagnosis;
three received open biopsy only, 12 patients with spine
lesions had anterior decompression or laminectomy with or
without tumour removal and the others received tumour
resection. Local radiation therapy with external megavoltage
irradiation was given to 17 patients post-operatively with the
radiation doses ranging from 3000 cGy in 15 fractions over 3
weeks to 5000cGy in 25 fractions over 5 weeks; local control
was achieved in all of these patients.
Of the 17 patients who received radiation therapy, five
were also treated with melphalan and prednisolone for a
persistent low level of M-protein following radiation therapy.
One patient (patient 20) had a local recurrence at a site just
above the previous radiation field 18 months later, and three
patients had disease progression after radiotherapy. Patient 1
developed a new lytic bone lesion in the skull 23 months
later, which was followed by the development of extramedul-
lary tumours in the nasal cavity, liver and left clavicle at 70
months; these lesions responded to local radiotherapy and
adjuvant chemotherapy. She died of disease dissemination to
multiple subcutaneous tissues, nrght breast and cervical
lymph nodes, without evidence of plasmacytosis in the bone
marrow at 87 months. Patient 4 had a new lesion at L2
vertebra at 7 months after diagnosis, which progressed to
MM 3 months later. Both patients received chemotherapy
following disease progression without long-term benefit.
Patient 13 developed multiple retroperitoneal and intra-
abdominal lymph nodes dissemination which responded
dramatically to combination chemotherapy with,cyclophos-
phamide, doxorubicin, vincristine and dexamethasone.
Unfortunately, he died of pneumonia. Patient 16 died of
hepatic failure at 4.5 months when he was in complete remis-
sion for SPB. The remaining 12 patients were still alive with
a median follow-up of 42 months; eight patients were in
continuous complete response and four were in apparent
remission.
Chemotherapy was the primary therapy for patients 2 and
6, and both had detectable paraprotein at diagnosis. Patient
2 developed a new bone lesion in the left proximal humerus
at 8 months while still on chemotherapy, which was followed
by multiple bone metastases, and he died 18 months after
diagnosis. Patient 6 received melphalan and prednisolone for
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Table I Clinical features and therapy response of 22 patients with solitary plasmacytoma of bone
Tumour Radiotherapy Chemo- Survival DFS
Case Agelsex locationa Surgery (cGy/fractions) therapy Outcome (months) (months)
1 56/F L4 Laminectomy 3450/19fx COP MEMP and 87 23
MBM,DOD
2 53/M L3 Open biopsy MP MBM,DOD 18 0
3 51/F C6 Tumour excision and curettage - - LR,DOD 49 32
4 54/M T10 Tumour excision and anterior 4100/20fx MP MM,DOD 14.5 6
stabilization
5 50/M T9 10 Tumour excision and anterior 3300/15fx MPb AR 103+ 101+
fusion
6 49/M Left clavicle Open biopsy MP NED 102+ 82+
7 33/F Skull Craniotomy and complete - MBM,AWD 79+ 35
tumour excision
8 21 /F Skull Craniotomy and complete 5000/25fx - NED 87+ 85+
tumour excision
9 36 M L2 Anterior decompression and fusion 3600/18fx - NED 84+ 83 +
10 521M T3 Laminectomy 4050/19fx - NED 79+ 78+
11 58/M Left ilium Open biopsy 5000/25fx MPb NED 52+ 49+
12 40/M Skull Craniotomy and tumour excision 5000/25fx NED 48+ 46+
13 71 'M T9-10 Anterior decompression and 5000/25fx VAD MEMP,DOD 6 2
fusion
14 58/M C6 Anterior decompression and 3000/15fx MPb AR 35+ 34+
interbody fusion
15 63/M C3-6 Tumour excision DOD 0.8 0
16 65/M Right femur Complete resection of tumour 5000/25fx - DOID 4.5 3
17 401M Skull Craniotomy and tumour excision 5000/25fx NED 30+ 28+
18 64/M T5 Laminectomy 4600/23fx MPb AR 25+ 24+
19 61/M L4-5 Laminectomy and tumour removal 5000/19fx NED 23+ 22+
20 57/F T4 Laminectomy and tumour removal 3600/12fx MP LR 22+ 18
21 42/M T6-8 Laminectomy and tumour removal 5000/25fx NED 17+ 15+
22 62/M L4-5 Laminectomy 4500/25fx Mpb AR 12+ 9
aC, cervical; T, thoracic; L, lumbarvertebra. bAdjuvant chemotherapy after local irradiation: AR, apparent remission; AWD, alive with disease; COP, cyclophosphamide, vincristine and prednisolone; DFS, disease-free survival; DOD, died of disease; DOID, died of intercurrent disease; LR, local recurrence; MBM, multiple bone metastases; MEMP, multiple extramedulary plasmacytomas; MM, multiple myeloma; MP,
melphalan and prednisolone; NED, no evidence of disease; VAD, vincristine, adriamycin and dexamethasone.
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20 months and has been disease free for 82 + months.
Two patients refused radiation therapy after complete
tumour resection; patient 3 had a local recurrence at 32
months and patient 7 developed multiple bone metastases at
35 months. Patient 15 died of suffocation 25 days after
surgery just before the initiation of radiotherapy.
The M-protein levels in SPB at diagnosis, following initial
therapy with local irradiation and/or chemotherapy, and at
local recurrence or disease progression are shown in Table II.
An M-protein was present in the serum or urine at diagnosis
in eight patients, including three, IgG, three IgA and two
light chains. Uninvolved immunoglobulins were normal in
all. Of the eight patients with M-protein at presentation, the
paraprotein disappeared in three, was reduced in two and
remained at a stable level in one after initial therapy, with
long-term local control being achieved in all of these six
patients; the other two patients who soon developed disease
progression had an elevated M-protein level at the time of
disease progression. There were five patients who did not
have M-protein at diagnosis; the appearance of M-protein
was associated with local recurrence or disease progression in
three patients, but one patient (patient 20) still had no detect-
able M-protein at the time of local relapse, and one patient
(patient 3) did not have M-protein determination at the time
of local recurrence.
Of the entire group of SPB patients, seven died, of whom
five succumbed to disease and two died of other causes. Of
the 15 SPB patients who survived, the median follow-up time
was 48 months with a range from 12 months to 103 months.
The overall 5 year survival rate was 68% and the 5 year
disease-free survival rate was 58% (Figure 1). The influence
of various factors on the outcome of the patients was
analysed, and patients aged less than 60 years were found to
have a significantly favourable overall survival (Table III).
Patients receiving local irradiation tended to have a lower
relapse rate than those without radiotherapy, but the differ-
ence was not statistically significnt. For the 17 patients who
received local irradiation, the overall 5 year survival rate and
disease-free survival rate were 82% and 72% respectively; we
did not find a correlation between radiation doses and the
outcome. Location of tumour, status of M-protein at diag-
nosis and chemotherapy did not correlate significantly with
overall survival, disease-free survival or the occurrence of
failure.
Extramnedullary plasmacytoma
The clinical characteristics and treatment results of the ten
patients with EMP are shown in Table IV. There were nine
men and one woman with ages ranging from 27 to 73 years
(median 63 years). The primary sites of EMP included
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Table m Prognostic factors in SPB
P-value
Overall Disease-free Relapse
Prognostic factor survival survival rate
Age>60 vs <60 0.02 0.87 0.62
Spine vs pernpheral bone 0.21 0.12 0.34
M-protein (+) vs (-) 0.60 0.66 0.66
Radiotherapy (+) vs (-) 0.24 0.16 0.09
Radiation doses (cGy)
>4000 vs <4000 0.50 0.24 0.55
)4500 vs <4500 0.99 0.26 0.25
;5000 vs <5000 0.74 0.26 0.59
Chemodthrapy (+) vs (-) 0.22 0.25 0.34
nasopharynx in four cases, paranasal sinuses in two cases
and nasal cavity, oropharynx, tonsil and jejunum in one case
each. Three patients also had regional lymph node involve-
ment. The presenting symptoms were related to the sites of
the primary disease and the mass effect of the lesions includ-
ing epistaxis, nasal obstruction, cheek swelling, neck mass,
abnormal feeling in the throat or swallowing discomfort; the
only patient with EMP in the small bowel presented with
abdominal pain. M-protein was present in six of the ten
patients with EMP at diagnosis; four had IgG-K and two
had IgG-L. Normal IgM and IgA levels were preserved in
all.
Table U M-protein level at diagnosis and during follow-up in patients with SPB and EMP
Case At diagnosis
SPB
1
2
4
5
6
7
11
13
14
18
22
EMP
I
2
3
4
7
8
After initial therapy
L-light chain (680 mg 24 h ' urine)
IgA-L (1016mgdl-')
IgG-L (1900 mgdi')
K-light chain (794mg24h-' urine)
IgG-L (1780 mgdl')
IgA-K (901 mg dl-')
IgG-K (I19Omgdl-')
IgA-K (910 mgd1')
IgG-L (2460 mg dl-')
IgG-K (3410mgdl-')
IgG-K (2730 mgdl-')
IgG-K (2260 mgdl-')
IgG-K (3970mgdl ')
IgG-L (945 mgdl-')
IgA-L (660mgdl-1')
IgG-K (1390mgdl-')
IgA-K (448mgdl1')
IgG-K (3680 mgdl-')
At recurrence or progression
L-light chain (1326 mg 24 h-' urine)
L-light chain (1640 mg 24 h ' urine)
IgA-K (2740mgdl-1')
IgG-L (1730 mgdl-')
IgG-L (4110 mg dl-')
IgG-K (2640 mg dl-')
IgG-K (2090mgd1-')
IgG-K (10400 mg dl-')
IgG-L (1270 mg dl-')
vThe patients with absence of M-protein are not listed. bIxncdig radiotherapy and/or chemotherapy.
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Four patients underwent surgical excision of tumours; two
of them also received post-operative local irradiation and
another (patient 1) received combination chemotherapy. Of
the remaimmng six patients who received biopsy for patho-
logical diagnosis, radiotherapy was the primary therapy in
four. Patient 7 refused radiation therapy and received com-
bination chemotherapy with vincristine, melphalan, cyclo-
phosphamide and prednisolone. He had a partial response
and developed MM 64 months later. Patient 8 was initially
diagnosed as having diffuse large-cell lymphoma of the
paranasal sinuses, and he achieved complete remission after
treatment with cyclophosphamide, doxorubicin, vincristine
and prednisolone. He had a local recurrence in the nasal
cavity 30 months later, with a biopsy of the relapsed tumour
demonstrating a plasmacytoma and a review of the previous
section also showing the same histology. He then received
local irradiation and has been free ofdisease for 32+ months
since local recurrence.
For the seven patients who received radiotherapy, the
radiation doses ranged from 4700 cGy in 21 fractions to
6500 cGy in 36 fractions; local control was achieved in all
patients. Patient 3 had a relapse in a lower cervical lymph
node just below the previous radiation field at 9 years.
Patient 4 developed a compression fracture at L2 spine with
spinal cord compression at 38 months, for which he received
local irradiation with adjuvant chemotherapy, and he has
had no evidence of disease for 79+ months thereafter.
As shown in Table II, M-protein was present in six
patients with EMP at diagnosis, and disappeared after
therapy in five patients in whom local control was achieved.
Reappearance of M-protein was found at the time of local
recurrence in two patients. M-protein remained constant in
patient 7, who had a partial response to combination
chemotherapy, and the development of MM in this patient
was associated with a marked elevation of the M-protein
level.
Of the patients with EMP, one was lost to follow-up at 22
months; the others have survived so far for 40+ to 147 +
months with a median follow-up time of 95 months. The
disease-free survival rates at 5 years, 8 years and 10 years
were 79%, 63% and 32% respectively, with a median
disease-free survival of 106 months (Figure 2). There was no
statistical difference between age groups (>60 years vs <60
years) and relapse rate (P = 1.0) or disease-free survival
(P = 0.84). Patients with regional lymph node involvement
did not have an increased risk of relapse (P = 0.50) or an
inferior disease-free survival (P = 0.56). The presence or
absence of M-protein at diagnosis did not significantly
influence the relapse rate (P = 0.08) and disease-free survival
(P = 0.13). Patients who received chemotherapy did not have
a lower relapse rate (P = 0.19) or favourable disease-free
survival (P = 0.18).
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Comparison between SPB and EMP
The age distribution and M-protein status at diais in
patients with SPB and EMP were not signiianly different
(P = 0.12 and P= 0.27 respectively). Seven pats with SPB
had evidenc of relap compared with four patients with
EMP, the incdence of repsw and the patters of relapse
were not significntly differet between the two groups
(P = 0.69 and P = 0.76 respectively). Patients with EP had
a better oveall survival than those with SPB (P = 0.03), but
there was no signnt difference in the disease-free survival
between the two groups (P = 0.53).
SPB and EMP repesented 6.2% and 2.8%, res ivly, of
all plasma cell neoplasms in Taiwan. These frequencies of
lalised plasaytomas were similar to those reported from
Westen countries (Corwin and Lindberg, 1979; Knowling et
al., 1983; Wolklsheim et al., 1984; Mayr et al., 1990;
Dimopoulos et al., 1992). The age distribution, male pre-
dominance and the prmary sites of tumours in our patients
were also similar to those obsrved in Western countms
(Kotner and Wang, 1972; Wiltshaw, 1976; Pahor, 1977;
Knowling et al., 1983; Meis et al., 1987; Mayr et al., 1990;
Holland et al., 1992). SPB usually occurred in the bones
characefisticaly affected in MM, and EMP was most fre-
quently located in the oronasopharynx and ranasal simuses,
with a 15-30% incidence of regional lymph node involve-
ment.
In the present series, 60% of EMP and 36% of SPB had
evidence of M-protein secretion at diagnosis. In comparison
with a 0-50% incidence of M-protein for EMP and an
18-82% incidence for SPB in other reported series (Tong et
al., 1980; Bataille and Sany, 1981; Harwood et al., 1981;
Knowling et al., 1983; Chak et al., 1987; Grenberg et al.,
1987; Frassica et al., 1989; Dimopoulos et al., 1992; Els &
Colls, 1992), our patients with EMP had a higher i
of M-protein. All patients in this study had serm and urin
protein electrophoresis and immunetrophoresis tests per-
formed, whereas most other seres did not have noelec-
trophoresis examinaton performed in all their patients. Since
protein elrophoresis is not as sensitive as imm lectro-
phoresis for the detection of M-protein, it is possible that the
incidence of M-protein in EMP might have been hiher in
the earler series if immunectrophoresis had been avail-
able. Local reLurrence or disease dmination was associ-
ated with the appearance, reapearance or elevation in the
lvel of M-rotein in both SPB and EMP, which suggets
that M-protein is important for monitoring the diseas
course and change in the M-protein status following initial
therapy should prompt reaessment and close follow-up.
Long-term local control for localised pla tomas can
be achieved by adequate local treatment. Both SPB and EMP
are sensitive to adequate doses of radiation therapy,however,
there is no clear dose-response relationship. Most inves-
tigators recommend tumour doses for localised plasma-
cytomas ranging from 3500 to 5500cGy (Kotner and Wang,
1972; Meyer and Schulz, 1974; Corwin and lindberg, 1979;
Woodruff et al., 1979ab; Mill et al., 1980; Mendenhall et al.,
1980; Harwood et al., 1981; Bush et al., 1981; Knowling et
al., 1983; Greenberg et al., 1987; Frssica et al., 1989),
whereas others have found that local failure can occur with
doses greater than 6000cGy in patients with EMP (Petrovich
et al., 1977; Bush et al., 1981). Mendenhall et al. (1980), in a
review of the literature, found a 94% kocal control rate for
localised plasaytoma with doses in excess of 4000 cGy
compared with only 69% with doses lessthan 4000cGy. Of
our seven EMP patients treated with radiotherapy, none
reeied lessthan 4500cGy and local control was achieved in
all. One patient developed cervicl node recurrejust out-
side the margin of the previous radiation area, which sup-
ports the statement that regional lymph nodes should be
included in the initial radiation fields for the treatment of
EMP (Knowling et al., 1983; Mayr et al., 1990). In patients
with SPB, espeially in those with spinal lesions, we found
that 3000cGy in 3 weeks provided good local control with
minimal morbidity, and radiation doses did not correlate
with outcome.
The efficacy of chemotherapy for localised plasacytomas
is difficult to assess from the literature. Three recent reports
demonstrated that adjuvant chemotherapy might increase the
clearance rate ofM-protein and could delay MM progression
(Mayr et al., 1990; Jackson and Scarffe, 1990; Holland et al.,
1992). However, we and Delauche-Cavalier et al. (1988)
failed to find any benefit on the outcome of patients who
recived cheotherapy. Furthermore, an increased risk of
therapy-related acute leukaemia following protracted courses
of alkylating chemotherapy has been observed (Bergsagel et
al., 1979; Delauche-Cavaller et al., 1988). Although the small
number of patients rewiving chemotherapy and lack of
uniform treatment in the reported series, including this
report, preclude any firm conclusion, we believe that
adjuvant chemotherapy has limited value in the nagement
of klased plasmytos if patients receiv adequate local
therapy with complete response. The role ofadjuvant chemo-
therapy for patients with a stent M-protein remains
unsetted. Some authors claimed that persisece of an M-
protein after local therapy indicated residual tumour or
occult diination for which adjuvant therapy was sug-
gested (Corwin and Lindberg, 1979; Woodruff et al., 1979b;
Bataille and Sany, 1981; Jackson and Scarffe, 1990; Mayr et
al., 1990); however, some of our patients with a persistent
low lel of M-protein have been in long-term apparent
remission without further chemotherapy. Frassica et al.
(1989) also found that a stable M-protein level might persist
for a long time without therapy; they even demonstrated that
sistence of M-protein after local therapy did not
signifiantly in outcome. In addition, the only two
patients who developed MM in the current sres received
chemotherapy as the primary therapy. These observations
suggest that the presence ofa low constant level ofM-protein
after initial therapy, in the absence of other evidnc of
progresson, does not necessarily indicate the need for
adjuvant chemotherapy, and also chemotherapy does not
prevent MM progression.
In the analysis of prognostic factors, there are conflicting
results as to whether advanced age, presence of an M-protein
or site ofdisease confers a poor prognosis. Our results are in
agreement with those reported by Harwood et al. (1981),
Chak et al. (1987), Frassica et al. (1989) and Jackson and
Scarffe (1990) that M-protein does not significntly influence
subsequent disease progression or survival, but are contrary
to the results of others who found that the presence of
M-rotein indicated a higher indence of MM progression
and a worse survival (Knowling et al., 1983; Delauche-
Cavallier et al., 1988; Dimopoulos et al., 1992; Holland et al.,
1992). BataiLle and Sany (1981) found that advanced age and
spinal involvement were associated with a higher rate of
progreson, whereas we found that advanced age was
unfavourabUe towards overall survival in SPB, but did not
affect the relapse rate or disease-free survival in SPB or
influene prognosis in EMP. Also, we failed to demonstrate
that spinal lesions were associated with an increased risk of
progression or a worse survival rate.
In three of the four patients who had a local relapse in the
present series, this occurred within 3 years and in the remain-
ing cas at 9 years. Wiltshaw (1976), in an analysis of the
combined series of localised plasaomas, found that local
curr occurred mostly during the first 5 years after
initial treatment but that relapse might occur more than 15
years later. Progression of SPB might take the form of
metasis to soft tissues or to other bones; similarly, EMP
occasionally disseminated to the bones. Two of our patients
with SPB ran a unique clinical course; they developed multi-
ple sequential EMP and/or multiple new lytic bone lesions
without bone marrow plasmacytosis. Bataille and Sany
(1981) reported that new solitary lesions developed in 15% of
their patients and, of these, 75% later converted to MM.Localised plasmacytomas in Taiwan
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Whether the development of a secondary solitary plas-
macytoma is a harbinger of ultimate conversion to MM and
whether multiple bone metastases represents a particular pat-
tern of spread different from MM are both unclear.
Dimopoulos et al. (1992) observed a median time of 20
months for evolution from SPB to MM, with 68% of cases
occurring within 3 years. Progression of SPB to MM was
infrequent in our patients, as was the case for those of
Delauche-Cavallier et al. (1988), compared with 40-75% of
cases in other series (Meyer and Schulz, 1974; Woodruff et
al., 1979b; Bataille and Sany, 1981; Chak et al., 1987; Fras-
sica et al., 1989; Dimopoulos et al., 1992). The high incidence
and rapid evolution to MM in the reported cases may be
attributed to the understaging of the patients at initial inves-
tigation (Dimopoulos et al., 1992).
Several reports in the literature have stressed that the
difference between SPB and EMP is that EMP tends to
remain localised whereas SPB appears to evolve more readily
into MM. In the present study, the development into MM
was seen in one patient each in both groups; the incidence
and patterns of failure between SPB and EMP were not
significantly different. The results of this present series con-
trast with the findings of a lower frequency of MM evolution
from EMP than from SPB in other studies (Wiltshaw, 1976;
Corwin and Lindberg, 1979; Knowling et al., 1983; Green-
berg et al., 1987; Mayr et al., 1990; Holland et al., 1992). Our
experience supports the observation of Meis et al. (1987) that
SPB and EMP appear to be more closely related than has
been previously recognised, and we also agree that it is useful
to continue to classify and distinguish the two groups from
each other for the purpose of treatment and continuing
understanding of the natural course of localised plasma-
cytomas.
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